Shuck-Bello CE, Leos-Acosta CA, Camarena-Reynoso HR, Vázquez-Ortega LS, Cantellano-Orozco M, Parraguirre S, Mata-Miranda P, Morales-Montor JG, Pacheco- Gabhler C, Calderón-Ferro F

Language: Spanish
References: 13
Page: 94-97
PDF size: 1919.69 Kb.

ABSTRACT

Introduction: Superficial bladder cancer prognosis factors have been a controversial topic and the subject matter of various medical articles over the years. Currently cystoscopy and urinary cytology are the gold standard for transitional cell carcinoma surveillance. However, cystoscopy is an expensive study, is uncomfortable for the patient and can be the cause of infection or trauma.
Materials and Methods: A retrolective review of case records of all patients presenting superficial bladder cancer from January 1990 to January 2007 was carried out. Statistical analysis was calculated by measures of central tendency and dispersion: range, mean, median, mode, standard deviation, proportion or percentage.
Results: Seventy patients diagnosed with superficial bladder cancer were analyzed. Sixty of them, 44 men (73%) and 16 women (26.6%), met the inclusion criteria and ranged in age from 19 to 91 years (mean age 59.2 years. Highest recurrence at one year presented in the intermediate risk group (77.7%) with a score of 5-9 points. Disease progression for the high risk group was 85.7%, presenting at 2 to 14 months. After 14 months there was no recurrence. The most important recurrence factors were tumor size and number.
Conclusions: Nomograms for predicting recurrence and progression are useful tools in the Mexican population, though they should be used merely as guides. It is necessary to evaluate a greater number of patients and a longer follow-up.

REFERENCES

1. Dalesio O, Schulman CC, Sylvester R et al. Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group. J Urol 1983;129(4):730-3.

2. Sylvester RJ, van der Meijden APM, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2 596 patients from seven EORTC trials. Eur Urol 2006 Mar;49:466-77.

3. Shariat SF, Zippe C, Lüdecke G, Boman H, et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 2005;173(5):1518-25.

4. Parmar MKB, Freedman LS, Hargreave TB et al. Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol 1989;142(2 pt 1):284-8.

5. Herr HW, Badalament RA, Amato DA et al. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 1989;141(1):22-9.

6. Kiemeney LALM, Witjes JA, Heijbroek RP et al. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993;150:60-4.

7. Kurth KH, Denis L, Bouffioux Ch et al. Factors affecting recurrence and progression in superficial bladder tumors. Eur J Cancer 1995;31(11):1840-6.

8. Allard P, Bernard P, Fradet Y, Têtu B. The early clinical course of primary Ta and T1 bladder cancer: a proponed prognostic index. Br J Urol 1998;81(5):692-8.

9. Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000;163(1):73-8.

10. Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000;164(3 Pt 1):680-4.

11. Solsona E, Iborra I, Dumont R et al. The 3 month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 2000;164(3 Pt 1):685-9.

12. Kaasinen E, Rintala E, Hellström P et al. Finn Bladder Group. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 2002;42(2):167-74.

13. Kwak C, Hyeon Ku J, Park JY et al. Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer. J Urol 2004;171(1):149-52.